Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX-009 Monotherapy or Combination With CTX-471 in Recurrent Glioblastoma
NCT07392957Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tovecimig in glioblastoma (GBM), sponsored by Washington University School of Medicine. Started Jun 2026; status: recruiting.
02
Drugs
tovecimig
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07392957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07392957.